BPC-157

Bpc-157 is a synthetic pentadecapeptide derived from a fragment of a human gastric juice protein, investigated for cytoprotective, angiogenic, and tissue-regenerative effects across multiple organ systems. It is not FDA-approved for any indication and remains an investigational compound; it is being studied in early-phase human trials for musculoskeletal injury recovery and has been administered orally and by subcutaneous injection in research settings. Currently, no pharmaceutical-grade formulation, validated dosing regimen, or completed Phase II clinical trial exists for Bpc-157.

What is Bpc-157?

Bpc-157 is a lab-made peptide (a small chain of amino acids) that was originally identified from a substance found in the stomach. Researchers have been studying it for its possible role in helping the body heal tissue, such as tendons, muscles, and the lining of the gut. It is important to know that Bpc-157 is not approved by the FDA for any use. It is still considered experimental, and doctors and scientists are only beginning to study it carefully in people.

How does it work?

Scientists do not yet fully understand exactly how Bpc-157 works in the human body. Some early lab studies suggest it may help blood vessels relax and may support tissue repair, but the exact mechanism is not yet established.

What is it used for?

Bpc-157 is being studied in research settings for things like helping tendons heal after rotator cuff (shoulder) surgery and helping recovery from hamstring muscle strains. These are still research studies, not approved treatments, and it is not currently proven to work for these purposes in people.

How is it given?

In research studies, Bpc-157 has been given by mouth (as a tablet) or as an injection under the skin. If your provider has prescribed a compounded preparation of Bpc-157 for you, always follow the directions on your own prescription label — do not use doses or schedules you read about online or in research articles, since those were used only under close medical supervision in study settings.

Common side effects

Because Bpc-157 has not been studied in large, well-controlled human trials, a reliable list of common side effects is not established in the available sources. Do not assume it is free of risk simply because it is derived from a natural substance.

When to call your doctor

Call your doctor or care team right away if you notice any unexpected symptoms after taking or injecting Bpc-157, including but not limited to signs of infection at an injection site (redness, warmth, swelling, pus), allergic reaction (rash, swelling of the face or throat, difficulty breathing), or any new or worsening symptoms you are concerned about.

Important warnings

• Bpc-157 is investigational and not FDA-approved. Long-term safety in humans has not been established.

• Do not use Bpc-157 if you are pregnant or breastfeeding — safety in these situations has not been studied.

• Tell your provider about all other medications and supplements you take, and about any history of autoimmune disease, diabetes, active infection, or blood-borne infectious disease before starting any peptide therapy.

• Because robust human safety and effectiveness data are lacking, discuss realistic expectations with your provider before starting treatment, and do not use it as a substitute for standard medical or orthopedic care recommended by your doctor.

Absorption and Bioavailability

A pharmaceutical review cited in the available sources reports that Bpc-157 demonstrates unusual stability in gastric juice and shows biological activity via oral, parenteral, and topical routes in preclinical work. Preclinical intramuscular bioavailability has been reported as ranging from 14% to 51% depending on the animal species studied. Human bioavailability data are not established in the available sources beyond a preliminary two-subject human pilot pharmacokinetic assessment referenced in the review.

Distribution and Protein Binding

Distribution characteristics and plasma protein binding of Bpc-157 in humans are not established in the available sources.

Metabolism

Specific metabolic pathways for Bpc-157 are not established in the available sources.

Elimination and Half-Life

A preclinical ADME study across two animal species, together with a preliminary two-subject human pilot study referenced in the source literature, found a plasma half-life of under 30 minutes, with linear, dose-proportional kinetics. The source literature notes a pharmacokinetic-pharmacodynamic disconnect: despite this short plasma half-life, biological effects have been reported to persist for hours to days in preclinical models, a discrepancy with unresolved implications for dosing strategy.

Formal Human Pharmacokinetic Data

A registered Phase I, randomized, placebo-controlled pilot study assessed oral administration of Bpc-157 tablets in healthy volunteers, with single-dose (varying tablet counts) and multiple-dose (fixed tablet count given three times daily for two weeks) regimens, collecting serial blood and urine samples to characterize Tmax, Cmax, T1/2, and AUC. Specific numeric pharmacokinetic results (Tmax, Cmax, T1/2, AUC values) and specific tablet-strength dose quantities from this trial are not established in the available sources.

Drug-Drug Interactions

Formal drug-drug interaction studies are not established in the available sources. No excipient compatibility or drug interaction data were identified in the reviewed literature.

Regulatory and Evidentiary Status

Bpc-157 is investigational and not FDA-approved. Comprehensive human safety data, including systematic adverse event rates, are not established in the available sources. The source literature explicitly notes that peptide supplements including Bpc-157 are often perceived by patients and athletes as low risk despite the absence of efficacy or safety data.

Contraindications

Specific absolute or relative contraindications for Bpc-157 are not established in the available sources. The Phase I trial excluded pregnant or lactating women, individuals with clinically significant ECG abnormalities, and those with active systemic infection; the rotator cuff trial excluded pregnant or breastfeeding individuals, those with active blood-borne infectious disease, diabetics, and those with a documented autoimmune disease diagnosis — these are research eligibility criteria and should not be interpreted as established clinical contraindications, but they may reflect areas of theoretical caution.

Adverse Effects

Specific rates or types of adverse effects attributable to Bpc-157 from completed trials are not established in the available sources. The registered Phase I trial's primary objective was systematic adverse event monitoring, but results were not reported in the available excerpts.

Monitoring Parameters

The Phase I protocol employed the following baseline laboratory and clinical monitoring parameters as eligibility/safety checks: leukocyte count, platelet count, hemoglobin, AST, ALT, bilirubin, creatinine, urine pregnancy testing, and ECG. Whether these represent required ongoing monitoring parameters for clinical use is not established in the available sources.

Special Populations

• Pregnancy/Lactation: Excluded from available clinical trials; safety in pregnancy and lactation is not established in the available sources.

• Pediatric: No pediatric data are established in the available sources; studied populations were adults 18 years and older.

• Geriatric: The Phase I trial enrolled subjects only up to age 35; geriatric-specific safety data are not established in the available sources.

• Renal/Hepatic Impairment: Not established in the available sources; the Phase I trial excluded subjects with significantly abnormal renal or hepatic laboratory values, but formal impairment-based safety data are not established.

• Autoimmune disease, diabetes, active infection: These conditions were exclusion criteria in registered trials; safety in these populations is not established in the available sources.

Broader Class Safety Signal

A scoping review of emerging musculoskeletal peptides (including Bpc-157) reported that some peptides in this class carry documented risks such as cardiovascular complications and metabolic dysfunction (including insulin resistance); the review did not attribute specific adverse effect data to Bpc-157 individually in the excerpted text, and it emphasized that robust safety data for Bpc-157 specifically are lacking.

Phase I Safety and Pharmacokinetics (Oral)

A single-center, randomized, placebo-controlled Phase I pilot study enrolled 42 healthy volunteers (ages 18–35) to assess the safety and pharmacokinetics of oral Bpc-157 tablets. The study used a two-part design: Phase 1a evaluated single ascending doses (across three tablet-count cohorts) with dose escalation contingent on the absence of severe adverse events, including a fed/fasted comparison at the middle-dose cohort; Phase 1b evaluated repeated dosing (a fixed tablet count given three times daily for 14 days) in an ambulatory setting. Primary outcomes were adverse event monitoring; secondary outcomes were pharmacokinetic parameters (Tmax, Cmax, T1/2, AUC). Specific tablet-strength dose quantities, as well as efficacy or detailed safety results from this trial, are not established in the available sources.

Rotator Cuff Repair Recovery (Subcutaneous)

A randomized, double-blind, placebo-controlled pilot trial is evaluating subcutaneous Bpc-157 (self-administered daily injections for 90 days) versus saline placebo in 20 patients following arthroscopic rotator cuff repair, assessing tendon healing via MRI, patient-reported outcomes, range of motion, dynamometry-measured strength, and biomarkers of collagen turnover and inflammation. This trial is designed to evaluate safety, feasibility, and preliminary efficacy; the source materials note that Bpc-157 has demonstrated regenerative and anti-inflammatory effects in preclinical musculoskeletal injury models but has not yet been studied in formal human clinical trials. Results of this trial are not established in the available sources.

Acute Hamstring Muscle Strain

A registered clinical trial is evaluating Bpc-157 for acute hamstring muscle strain repair. Detailed methodology, dosing, and results for this trial are not established in the available sources beyond its registration.

Scoping Review of Musculoskeletal Applications

A PRISMA-guided scoping review of six emerging peptides (including Bpc-157) found that 67% of identified publications used preclinical animal models, with promising but variable effects on tendon, muscle, bone, and ligament healing. Human clinical studies were limited in number and generally lacked robust controls or rigorous design. The review concluded that claimed musculoskeletal recovery and performance benefits of these peptides, including Bpc-157, remain unsubstantiated by current human trials, and that documented risks among the peptide class include cardiovascular complications and metabolic dysfunction (attributed in the review predominantly to other peptides in the group, e.g., growth hormone secretagogues).

Gerontology Review

A narrative review of therapeutic peptides in aging identified Bpc-157 among peptides studied for tissue repair, noting promising preclinical and limited clinical evidence but a lack of long-term safety data and systematic validation, with significant knowledge gaps in optimal dosing regimens.

Vascular Pharmacology

An ex vivo study in isolated human internal mammary artery segments reported endothelium-dependent, nitric oxide-mediated vasorelaxant effects of Bpc-157; clinical significance of this finding in vivo is not established in the available sources.

Overall Evidentiary Status

A recent biopharmaceutical review concludes that available human clinical data for Bpc-157 derive from fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations, and that no Phase II trial has been completed.